EHA 2025 | Results of the ITCC-059 study investigating inotuzumab ozogamicin in pediatric patients with R/R ALL
Erica Brivio, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, comments on the results of the Phase II ITCC-059 study (EUCTR 2023-504694-20-00), a trial investigating inotuzumab ozogamicin in pediatric patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Dr Brivio highlights that the study has shown inotuzumab to be effective in inducing remission in patients who experience early relapse following frontline treatment, and those with high-risk genetic characteristics. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
ITCC-059 study is a trial that started a few years ago in pediatric patients with a relapsed and refractory ALL. We already presented the results of the Phase I and Phase II single agent trial in multiple relapsed ALL. And then we also went on in a combination cohort with chemotherapy and this time at the EHA we are presenting the last cohort which is in first relapse ALL with very high risk characteristics and so this time we show that inotuzumab is also very effective in these children that are relapsing very early and so during frontline treatment or that have very high risk genetic characteristics...
ITCC-059 study is a trial that started a few years ago in pediatric patients with a relapsed and refractory ALL. We already presented the results of the Phase I and Phase II single agent trial in multiple relapsed ALL. And then we also went on in a combination cohort with chemotherapy and this time at the EHA we are presenting the last cohort which is in first relapse ALL with very high risk characteristics and so this time we show that inotuzumab is also very effective in these children that are relapsing very early and so during frontline treatment or that have very high risk genetic characteristics. Inotuzumab is confirmed to be a very active drug in inducing remission in these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Institutional funding: Pfizer.
